An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-Small Cell Lung Cancer.

Trial Profile

An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Patupilone (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 26 Aug 2015 Primary endpoint has been met. (Early progression (EP)) according to the results published in the Cancer
    • 26 Aug 2015 Primary endpoint has been met. (Progression-free survival (PFS9w)) according to the results published in the Cancer
    • 26 Aug 2015 Results published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top